|Videos|November 2, 2022
Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5